Nature Communications (Jun 2021)

Molecular benchmarks of a SARS-CoV-2 epidemic

  • Hakon Jonsson,
  • Olafur T. Magnusson,
  • Pall Melsted,
  • Jonas Berglund,
  • Arna B. Agustsdottir,
  • Berglind Eiríksdottir,
  • Run Fridriksdottir,
  • Elisabet Eir Garðarsdottir,
  • Gudmundur Georgsson,
  • Olafia S. Gretarsdottir,
  • Kjartan R. Guðmundsson,
  • Thora Rosa Gunnarsdottir,
  • Hannes Eggertsson,
  • Arnaldur Gylfason,
  • Hilma Holm,
  • Brynjar O. Jensson,
  • Aslaug Jonasdottir,
  • Frosti Jonsson,
  • Kamilla S. Josefsdottir,
  • Marianna Thordardottir,
  • Karl G. Kristinsson,
  • Þórður Kristjánsson,
  • Droplaug N. Magnusdottir,
  • Louise le Roux,
  • Jona Saemundsdottir,
  • Asgeir Sigurdsson,
  • Gudrun Sigmundsdottir,
  • Gardar Sveinbjornsson,
  • Solvi Rognvaldsson,
  • Ogmundur Eiriksson,
  • Magnus Karl Magnusson,
  • Kristin Eva Sveinsdottir,
  • Maney Sveinsdottir,
  • Emil Aron Thorarensen,
  • Bjarni Thorbjornsson,
  • Arthur Löve,
  • Gudmundur L. Norddahl,
  • Ingileif Jonsdottir,
  • Patrick Sulem,
  • Gisli Masson,
  • Alma Moller,
  • Thorolfur Gudnason,
  • Mar Kristjansson,
  • Agnar Helgason,
  • Daniel F. Gudbjartsson,
  • Unnur Thorsteinsdottir,
  • Kari Stefansson

DOI
https://doi.org/10.1038/s41467-021-23883-6
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 8

Abstract

Read online

The concentration of SARS-CoV-2 changes during an individual’s infection, and mutations accumulate as viruses are transmitted between people. Here, the authors use data from Iceland to demonstrate how this information can be exploited at the population-level to determine the phase of the epidemic.